Key features and details | |
Cat. No. | MABL-325 |
Name | Anti-5T4 mAbs |
Clone No. | AFD- A1 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | therapeutic, ELISA |
Species Reactivity | chimpanzee, Human, Cynomolgus Monkey |
Basic Information | |
Specificity | This antibody binds the ectodomain regions of human 5T4 antigen which is overexpressed by a wide spectrum of cancers, including colorectal, ovarian and gastric, but with a limited normal tissue expression. |
Alternative Name | TPBG; M6P1; WAIF1; Trophoblast glycoprotein; 5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; 5T4 oncotrophoblast glycoprotein; Wnt-activated inhibitory factor 1; PF-06263507; A1mcMMAF; A1-mcMMAF; A1-mafodotin |
UniProt | Q13641 |
Immunogen | The original mouse antibody was generated by immunizing mice with human 5T4 antigen. Later on the CDRs of the mouse antibody were grafted onto human framework regions to generate a fully human antibody. |
Application Notes | The epitope mapping of this antibody was done using ELISA. This antibody was used in the generation of an anti-5T4 antibody-drug conjugate (A1mcMMAF; PF 06263507) by sulfhydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F (MMAF) via a maleimidocaproyl linker. A1mcMMAF exhibited potent in vivo antitumor activity in a variety of tumor models and induced long-term regressions for up to 100 days after the last dose. In a non-small cell lung cancer patient-derived xenograft model, A1mcMMAF treatment resulted in sustained tumor regressions and reduced TIC frequency (PMID: 23223830). Treatment with A1mcMMAF significantly improved survival without overt toxicity in mice engrafted with a 5T4-positive acute lymphoblastic leukemia cell line (PMID: 28341731). The original humanized IgG antibody A1 has a Kd of 0.9 nM against the 5T4 antigen, binds to a broad range of 5T4 expressing cell lines, and rapidly internalizes (66% internalized within 4h). |
Antibody First Published | Sapra et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther. 2013 Jan;12(1):38-47. PMID:23223830 |
Note on publication | Describes the generation of an ADC that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells (TIC), using this antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
